Posted by Michael Wonder on 27 Apr 2026
Novartis Rhapsido receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
27 April 2026 - Novartis announced today that the European Commission approved Rhapsido (remibrutinib) for chronic spontaneous urticaria in adult patients with inadequate response to H1 anti-histamine treatment.
Rhapsido is the first oral targeted treatment approved for chronic spontaneous urticaria, offering a unique approach to chronic spontaneous urticaria treatment in a pill taken twice daily without any lab monitoring required.
